Inhibin-alpha subunit is an independent prognostic parameter in human endometrial carcinomas: Analysis of inhibin/activin-alpha, -betaA and -betaB subunits in 302 cases
详细信息 查看全文
- 作者：Ioannis Mylonas ; Silvia Worbs ; Naim Shabani ; Christina Kuhn ; Susanne Kunze ; S ; ra Schulze ; Darius Dian ; Andrea Gingelmaier ; Christian Schindlbeck ; Ansgar Brü ; ning ; Harald Sommer ; Udo Jeschke ; Klaus
- 关键词：Endometrium ; Cancer ; Immunohistochemistry ; Inhibin-alpha ; Inhibin-betaA ; Inhibin-betaB ; Prognosis ; Survival
- 刊名：European Journal of Cancer
- 出版年：2009
- 出版时间：May 2009
- 年：2009
- 卷：45
- 期：7
- 页码：1304-1314
- 全文大小：674 K
文摘
Inhibins are dimeric glycoproteins, composed of an alpha-subunit (inhibin-α) and one of two possible beta-subunits (βA or βB), with substantial roles in human reproduction and in endocrine-responsive tumours. The aims of this study were to determine the distribution of inhibin-α, -βA and -βB subunits in malignant human endometrial tissue and the assessment of an association with specific clinicopathologic tumour features and clinical outcome. A series of 302 endometrial cancer tissue samples were immunohistochemically analysed with monoclonal antibodies against inhibin subunits. The inhibin-α subunit showed a significant association with histological grading, surgical staging, lymph node status and diabetes in patients with endometrial cancer. Interestingly, loss of inhibin-α expression resulted in a poorer survival of endometrial cancer patients. Additionally, survival analysis demonstrated that inhibin-α immunoreactivity was an independent prognostic factor for progression-free survival, cause-specific survival as well as for overall survival. In contrast, although inhibin-βA- and -βB subunits showed a significant association between endometrial histological subtypes and histological grading, both subunits were not found to be associated with survival in endometrial cancer patients. Therefore, inhibin-α immunostaining might be used as a simple and efficient marker to identify high-risk patients leading to the selection of patients for an aggressive adjuvant therapy.